Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q4 2023 Earnings Presentation
9 slides from Sanuwave Health's earnings presentation, Mar 22, 2024
Slide 1: Q4 and FY2023
(6) SANUWAVE Wound Care Technologies Q4 and FY2023 March 22, 2024
Slide 2: Live Presentation and Participant Dial-in Information
Live Presentation Friday, March 22, 2024, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1661785&tp_key=8f8d9c1839 Replay Dial-in Infor
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company’s current views with respect to certain current and future events and financial performance. Forward-looking sta
Slide 4: Financials Q4 2023
4 Financials Q4 2023 Consistent topline growth while managing operating costs. (in millions) Q4 2023 Q4 2022 YoY Revenue $7.0 $5.5 + 27% Gross Profit $4.8 $4.3 + 12% Gross Margin 69.1%* 78.4%* - 930bp Operating $3.8 $5.8 -34% Expense Operating I n c o m e Operating Income $1.0 ($1.5) +171% Revenue G
Slide 5: Financials FY 2023
5 Financials FY 2023 Consistent topline growth while managing operating costs. (in millions) FY 2023 FY 2022 YoY Revenue $20.4 $16.7 + 22% Gross Profit $14.4 $12.4 + 16% Gross Margin 70.4% 74.1% - 370bp Operating $14.9 $21.4 -30% Expense Operating Income ($0.5) ($9.0) +94% Revenue Gross Profit Opera
Slide 6: Improved operational profitability
6 Improved operational profitability Adjusted EBITDA For the quarter ended December 31, For the year ended (in thousands) 2023 2022 2023 2022 Net income (loss) $ 18,235 $ (5,697) $ (25,807) $ (10,293) Non-GAAP Adjustments: Interest expense 3,119 4,160 15,623 14,132 Depreciation and amortization 247
Slide 7: Growing UltraMist Systems & Consumables Sales
7 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth throughout 2023 • 666 Active Systems* in $4.0 + 21% yoy the field at end Q4 $3.5 +16% seq • In Q4 : 79 systems sold +37% yoy $3.0 and 19 systems in rent to +73% seq own program (RTO); total $2.5 of 98 (vs 28 in Q1, 4
Slide 8: Q1 and FY 2024 Revenue Guidance
8 Q1 and FY 2024 Revenue Guidance Q1 2024 FY 2024 REVENUE GROWTH REVENUE GROWTH +45-55% +50% Vs Vs Q1 2023 REVENUE FY 2023 REVENUE Of $3.8 million Of $20.4 million
Slide 9: Summary
9 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: § Approved products protected by strong IP § Strong existing reimbursement with room to impr